#mRESVIA

2개의 글

12 de mayo de 2026

MRNA Moderna Perspectivas 2026: La plataforma mRNA busca su segundo acto

Perspectivas de Moderna (MRNA) 2026: $7.500M en caja, vacuna mRESVIA RSV, intismeran autogene Fase 3 con Merck, ingresos FY2025 $1.940M, consenso Hold objetivo $36,82. Pipeline completo, escenarios de precio y análisis de riesgos para inversores de LATAM y España.

MRNA Moderna mRNA

May 12, 2026

MRNA Moderna Stock Outlook 2026: Does the mRNA Platform Have a Second Act?

Moderna (MRNA) stock outlook 2026: $7.5B cash runway, mRESVIA RSV launch, intismeran autogene Phase 3 with Merck, $1.94B FY2025 revenue, analyst Hold consensus at $36.82 target. Full pipeline, 3 price scenarios, and honest risk assessment for US investors.

MRNA Moderna mRNA